EMMA Emmaus Life Sciences, Inc.

Price Chart

Executive Summary

Emmaus Life Sciences entered into an Exclusive Supply Agreement with NeoImmuneTech (NIT) to supply Endari (L-glutamine) for sickle cell disease in the U.S. and Canada, contingent on NIT obtaining regulatory approval. Emmaus will supply the product at cost plus a double-digit margin, but the deal is not guaranteed as the effective date depends on regulatory milestones and could terminate by October 1, 2026 if not met.

Actionable Insight

Key Facts

• Emmaus Life Sciences (EMMA) entered into an Exclusive Supply Agreement with NeoImmuneTech (NIT) on March 2, 2026
• The agreement is contingent on NIT obtaining regulatory approvals to market and distribute Endari in the U.S. and Canada
• Emmaus will supply Endari to NIT at cost of production plus a double-digit percentage margin
• The License Agreement may be terminated by either party if the Effective Date does not occur by October 1, 2026, unless due to Emmaus' wrongful acts
• The supply agreement supports a prior license deal where NIT gained exclusive rights to market, sell, and distribute Endari in the U.S. and Canada for sickle cell disease

Financial Impact

Potential future revenue stream based on cost-plus margin, but no guaranteed financial impact due to regulatory contingencies

Risk Factors

• Deal may not close if NIT fails to obtain required regulatory approvals
• No assurance of revenue generation if the Effective Date does not occur by October 1, 2026
• Dependence on NIT's commercial execution in the U.S. and Canadian markets

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status